Serine/arginine-rich splicing factor 7 plays oncogenic roles through specific regulation of m6A RNA modification
Cun, Y.; An, S.; Zheng, H.; Lan, J.; Chen, W.; Luo, W.; Yao, C.; Li, X.; Huang, X.; Sun, X.; Wu, Z.; Hu, Y.; Li, Z.; Zhang, S.; Wu, G.; Yang, M.; Tang, M.; Yu, R.; Liao, X.; Gao, G.; Zhao, W.; Wang, J.; Li, J.
Show abstract
Serine/Arginine-Rich Splicing Factor 7 (SRSF7), which is previously recognized as a splicing factor, has been revealed to play oncogenic roles in multiple cancers. However, the mechanisms underlying its oncogenic roles have not been well addressed. Here, based on N6-methyladenosine (m6A) co-methylation network analysis across diverse cell lines, we found SRSF7 positively correlated with glioblastoma cell-specific m6A methylation. We then proved SRSF7 is a novel m6A regulator that specifically facilitates the m6A methylation near its binding sites on the mRNAs involved in cell proliferation and migration through recruiting methyltransferase complex. Moreover, SRSF7 promotes the proliferation and migration of glioblastoma cells largely dependent on the m6A methyltransferase. The two single-nucleotide m6A sites on PBK are regulated by SRSF7 and partially mediate the effects of SRSF7 on glioblastoma cells through recognition by IGF2BP2. Together, our discovery revealed a novel role of SRSF7 in regulating m6A and timely confirmed the existence and functional importance of RNA binding protein (RBP) mediated specific regulation of m6A.
Matching journals
The top 2 journals account for 50% of the predicted probability mass.